Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions not accepted

The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

Submissions

147 documents · page 1 of 5

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-CERTAINTY-FR/013Draft revision of the Institute’s certainty assessment framework…Dr Katarzyna Oppenheimer-AdeThe document should state what a reader ought to do
DRAFT-CERTAINTY-FR/012Draft revision of the Institute’s certainty assessment framework…Dr Bertrand Steenkamp-FerreiraThe document set should be published in translation
DRAFT-SUPPLIER-RUB/007Draft supplier evaluation rubricXenia Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-SUPPLIER-RUB/006Draft supplier evaluation rubricDr Rurik Haverkamp-Diallo industryThe document should not describe uses outside the approved indication
DRAFT-COA-MINIMUM-/007Draft certificate-of-analysis minimum data standardDr Fenella LavrentievThe document set should be published in translation
DRAFT-RP-HPLC-PURI/001Draft standard: determination of chromatographic purity by…Dr Quentin ZimmerthalThe standard should require documented operator competence
DRAFT-RP-HPLC-PURI/004Draft standard: determination of chromatographic purity by…Dr Theodora TrelawneyThe document set should be published in translation
DRAFT-SEMAGLUTIDE-/003Draft monograph: semaglutide, version 3Quentin Gwynne-Sarpong industryThe document should not describe uses outside the approved indication
DRAFT-TIRZEPATIDE-/013Draft monograph: tirzepatide, version 2Dr Melisande Kirkpatrick-OlaThe monograph should state what the compound costs
DRAFT-BPC-157-MONO/007Draft monograph: BPC-157Dr Hortensia Larsson-Ekwueme industryThe document should not describe uses outside the approved indication
DRAFT-WEIGHT-REGAI/015Draft synthesis: weight change after discontinuation of an incretin…Dr Jerome PetrossianThe document should state what a reader ought to do
DRAFT-WEIGHT-REGAI/006Draft synthesis: weight change after discontinuation of an incretin…Dr Ivo QuintanilhaThe review question is drawn too broadly to be answerable
DRAFT-NETWORK-TRAN/004Draft methodological review: transitivity in the incretin networkDr Henrike JastrzębskaThe document should state what a reader ought to do
DRAFT-CONFLICTS-PO/005Draft conflicts-of-interest policyDr Ludmila TollemacheRecusal should follow automatically from any declared financial interest
DRAFT-CONFLICTS-PO/003Draft conflicts-of-interest policyQuentin Gwynne-Sarpong industryThe document should not describe uses outside the approved indication
DRAFT-CONFLICTS-PO/001Draft conflicts-of-interest policyDr Ottoline Fitzgerald-NwosuThe document should state what a reader ought to do
DRAFT-FUNDING-POLI/007Draft funding and sponsorship policyDr Wilhelmina WintringhamThe document should state what a reader ought to do
DRAFT-FUNDING-POLI/003Draft funding and sponsorship policyDr Liesbeth Zaleski-MbekiRecusal should follow automatically from any declared financial interest
DRAFT-FUNDING-POLI/005Draft funding and sponsorship policyZdenka Ximenes industryThe document should not describe uses outside the approved indication
DRAFT-CITATION-POL/006Draft citation policyDr Ludmila Castellanos-ReidThe document set should be published in translation
DRAFT-CITATION-POL/009Draft citation policyDr Valentin Castellanos-ReidAnonymous submissions should be accepted where the respondent risks employment consequences
DRAFT-PROGRAMME-RE/006Draft policy: labelling of Institute-constructed programme recordsYusuf Whitmarsh-Obi industryThe document should not describe uses outside the approved indication
DRAFT-PROGRAMME-RE/008Draft policy: labelling of Institute-constructed programme recordsDr Katarzyna YorkstoneThe document should state what a reader ought to do
DRAFT-PROGRAMME-RE/004Draft policy: labelling of Institute-constructed programme recordsQuentin Gwynne-SarpongRecusal should follow automatically from any declared financial interest
DRAFT-ENDOTOXIN-ST/006Draft standard: bacterial endotoxin testing of peptide presentationsDr Wilhelmina ErlingssonThe document set should be published in translation
DRAFT-ANALYTICAL-S/009Draft scope of the analytical and methodological standards seriesDr Jolyon Grünbaum-SowandeThe document should state what a reader ought to do
DRAFT-GLP1-OBESITY/006Draft synthesis: glucagon-like peptide-1 receptor agonists for weight…Professor Chukwuemeka Rasmussen-AdeyemiThe document set should be published in translation
DRAFT-GASTROPARESI/006Draft safety review: delayed gastric emptying and procedural sedationHortensia Beauchamp-Ekong industryThe document should not describe uses outside the approved indication
DRAFT-SUPPLIER-DOS/005Draft format of the supplier dossier seriesZdenka Ximenes industryThe document should not describe uses outside the approved indication
DRAFT-PEOPLE-REGIS/011Draft policy on the register of members and reviewersDr Rurik Haverkamp-DialloThe document set should be published in translation

page 1 of 5

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.